Core Viewpoint - The company will present the latest research results of its self-developed products DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) conference [1] Group 1: Product DZD8586 - DZD8586 is aimed at treating B-cell non-Hodgkin lymphoma, with a focus on chronic lymphocytic leukemia/small lymphocytic lymphoma [1] - The efficacy and safety of DZD8586 will be showcased, particularly through a summary analysis included in an oral presentation [1] Group 2: Product DZD6008 - DZD6008 is a novel, highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor [1] - The product targets EGFR-mutant non-small cell lung cancer patients who have undergone multiple lines of treatment, including third-generation EGFR TKIs [1] - Positive research results for DZD6008 will be presented for the first time [1]

股票代码：688192 股票简称：迪哲医药 迪哲（江苏）医药股份有限公司 Dizal （Jiangsu） Pharmaceutical Co., Ltd. （无锡市新吴区和风路 26 号汇融商务广场 C 栋 404、405、416 室） 2023 年度向特定对象发行 A 股股票 上市公告书 保荐人（联席主承销商） 联席主承销商 二〇二五年四月 迪哲（江苏）医药股份有限公司 上市公告书 特别提示 一、发行股票数量及价格 1、发行数量：41,764,808 股 2、发行价格：43.00 元/股 3、募集资金总额：人民币 1,795,886,744.00 元 4、募集资金净额：人民币 1,773,446,130.53 元 二、本次发行股票预计上市时间 | স্থ | | --- | | 二、保荐人推荐公司本次发行新增股份上市的结论性意见 | | --- | | 36 | 本次发行新增股份在其限售期满的次一交易日在上交所科创板上市流通（预计 流通时间如遇法定节假日或休息日，则顺延至其后的第一个交易日）。 三、新增股份的限售安排 本次发行对象共有 14 家，均以现金参与认购，发行对象所认购的本次发行股 份自本次发行结束 ...

华泰联合证券有限责任公司 关于 迪哲（江苏）医药股份有限公司 2023 年度向特定对象发行 A 股股票 并在科创板上市之 上市保荐书 保荐机构（主承销商） （深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小镇 B7 栋 401） 上海证券交易所： 作为迪哲（江苏）医药股份有限公司（以下简称"发行人"、"公司"）2023 年度向特定对象发行 A 股股票并在科创板上市的保荐机构，华泰联合证券有限 责任公司及其保荐代表人已根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等法律法规和中国 证券监督管理委员会（以下简称"中国证监会"）及贵所的有关规定，诚实守信， 勤勉尽责，严格按照依法制定的业务规则和行业自律规范出具上市保荐书，并保 证所出具文件真实、准确、完整。 现将有关情况报告如下： 一、发行人基本情况 上市保荐书 华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 2023 年度向特定对象发行 A 股股票 并在科创板上市之上市保荐书 （一）发行人概况 公司名称：迪哲（江苏）医药股份有限公司 注册地址：无锡市新吴区和风路 26 号汇融 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-16 迪哲（江苏）医药股份有限公司 关于向特定对象发行股票发行结果暨股本变动的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 发行数量和价格 预计上市时间 本次发行对公司股本结构的影响 本次向特定对象发行的新股登记完成后，公司增加 41,764,808 股有限售 条件流通股。本次发行不会导致公司控制权发生变化。本次向特定对象发行 完成后，公司股权分布符合《上海证券交易所科创板股票上市规则》规定的 上市条件。 资产过户情况 本次发行的股票均以现金认购，不涉及资产过户的情况。 迪哲（江苏）医药股份有限公司（以下简称"公司"、"发行人"）本次 发行新增股份 41,764,808 股已于 2025 年 4 月 18 日在中国证券登记结算有限 责任公司上海分公司办理完成登记、托管及限售手续。 本次发行新增股份为有限售条件流通股，将于限售期届满后的次一交易 日起在上海证券交易所科创板上市流通交易，如遇法定节假日或休息日，则 顺延至其后的第一个交易日。 ...

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

证券代码：688192 证券简称：迪哲医药 公告编号：2025-15 迪哲（江苏）医药股份有限公司 自愿披露关于高瑞哲®列入《CSCO 淋巴瘤 诊疗指南（2025 版）》I 级推荐的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，迪哲（江苏）医药股份有限公司（以下简称"公司"）从中国临床肿 瘤学会（CSCO）指南发布会获悉，其自主研发的源头创新药物高瑞哲®（通用名： 戈利昔替尼胶囊）治疗复发/难治外周 T 细胞淋巴瘤（r/r PTCL）获《CSCO 淋巴 瘤诊疗指南（2025 版）》（以下简称"指南"）I 级推荐。此外，指南首次推荐 高瑞哲®单药治疗复发/难治 NK/T 细胞淋巴瘤（r/r NKTCL）患者，并提及高瑞 哲®针对 PTCL 维持治疗的探索。 CSCO 指南是中国肿瘤诊疗的重要参考，基于循证医学证据，兼顾诊疗产品 的可及性，吸收精准医学新进展制定。药物推荐方面，指南基于国内外研究成果 和专家意见，确定推荐等级，以指导临床实践。 一、关于高瑞哲® 此次提升推荐等级，是基于高瑞哲®一项单臂、全球多中心注 ...

Core Viewpoint - Dize Pharmaceutical successfully completed a private placement of A-shares, raising a total of 1.796 billion yuan, indicating strong market interest and recognition from institutional investors in the company's value and the innovative drug sector [2][3] Group 1: Fundraising Details - The private placement was priced at 43 yuan per share, which is 80% of the average price over the 20 trading days prior to the pricing date [2] - A total of 24 subscription entities participated, with 14 final allocation recipients, including well-known public funds and insurance capital [2] - Notable investors included Taikang Asset Management, Zhuque Fund Management, and UBS AG, highlighting the appeal of Dize Pharmaceutical to long-term capital [2] Group 2: Company Development and Products - The successful completion of the fundraising will accelerate the company's development and enhance shareholder value [3] - Dize Pharmaceutical is recognized as a representative of domestic innovative drugs, with two products, Shuwotai (舒沃替尼片) and Gaoruizhe (戈利昔替尼胶囊), already listed in China and included in the new national medical insurance catalog [3] - The company has submitted a marketing application for Shuwotai to the FDA, which has been accepted and prioritized for review, indicating potential for international expansion [3]

Group 1 - The core point of the news is that Dize Pharmaceutical is the first unprofitable company on the Shanghai Stock Exchange to receive registration for refinancing since the release of the "Kebatiaos" policy [1][2] - Dize Pharmaceutical completed a private placement of 1.796 billion yuan, with a share price set at 43.00 yuan per share, involving 24 subscription participants, including public funds and foreign institutional investors [1] - The purpose of the refinancing is to invest in new drug research and development, international standard innovative drug industrialization projects, and to supplement working capital [1] Group 2 - Dize Pharmaceutical has two products, Shuwozhe and Gaoruizhe, that have been launched in China and included in the new national medical insurance catalog, with Shuwozhe's application to the FDA accepted for priority review [1] - The company reported a net loss of 857 million yuan for 2024, which is a reduction of 251 million yuan compared to the previous year [1] - The capital market for biopharmaceuticals is showing signs of recovery, with over half of the 110 stocks in the Sci-Tech Innovation Board's biopharmaceutical sector having positive cumulative returns this year [2]

Core Viewpoint - The successful fundraising by Dizhe Pharmaceutical highlights the increasing recognition and support for innovative drug companies in China, particularly in the context of the "K8 Policy" and the growing interest from both domestic and international investors [1][3][8]. Fundraising Details - Dizhe Pharmaceutical announced the completion of a private placement, raising 1.796 billion yuan, making it the first unprofitable company on the Shanghai Stock Exchange to receive regulatory approval for refinancing since the "K8 Policy" was introduced [1][3]. - The placement was priced at 43.00 yuan per share, with a premium of over 12% compared to the average price over the previous 20 trading days [1]. - A total of 24 subscription entities participated, with 14 selected as allocation recipients, including major institutional investors such as pension funds, public funds, and specialized pharmaceutical investors [1][3]. Investor Composition - The diverse investor structure, including prominent domestic asset management firms and international representatives like UBS, is expected to provide strong financial support and strategic resources for Dizhe Pharmaceutical's future development [3][8]. Product Development and Internationalization - Dizhe Pharmaceutical has two products, Shuwozhe® and Gaoruizhe®, already listed in China and included in the 2024 National Medical Insurance Directory [4]. - Shuwozhe® has received breakthrough therapy designation in both China and the U.S., marking it as the first domestic Class I new drug to achieve such recognition in both countries [4]. - Gaoruizhe® is set to be approved in June 2024, addressing a decade-long gap in innovative treatments for peripheral T-cell lymphoma [4]. Significance of Fundraising - The funds raised will accelerate the research and clinical trials of the company's products and optimize its capital structure, enhancing its risk resilience [5][8]. - The successful fundraising reflects the broader trend of policy and capital support for domestic innovative drug companies, indicating a favorable market outlook for the sector [8]. Industry Context - The success of Dizhe Pharmaceutical's fundraising is indicative of a dual benefit period for domestic innovative drug companies, driven by supportive policies and expanding market opportunities [8]. - As the R&D capabilities of domestic companies improve and their internationalization efforts progress, leading firms are expected to play a more significant role in the global pharmaceutical innovation landscape [8].

4月16日，迪哲医药(688192)披露了向特定对象发行A股股票发行情况报告书，公司已顺利完成定增。定 价基准日为发行期首日即4月1日，发行价格不低于定价基准日前20个交易日的80%，即不低于38.10 元。根据最终的申购情况，本次发行价格确定为43.00元/股，发行股数为4176.48万股，募集资金总额为 17.96亿元。 根据发行情况报告书，共有24个认购对象参与了本次发行申购，其中包括多家市场主流大型机构投资 者，如中国人民养老保险、广发基金、富国基金、嘉实基金等。最终按照认购价格优先、认购金额优先 和收到《申购报价单》时间优先的原则确定了最终获配发行对象共计14名，其中包括多家知名公募基金 和保险资金为代表的长期耐心资本，如泰康资产、朱雀基金、鹏华基金、诺德基金、博时基金等，也有 瑞银(UBS)为代表的QFII外资机构投资者，以及无锡股权投资和生物医药产业基金，体现了无锡大力支 持生物医药产业发展的决心。 迪哲医药是"科八条"发布以来，再融资获得证监会注册的首家上交所未盈利企业。研究机构认为，本次 融资获得众多知名投资者认可和追捧，充分说明市场机构投资者对迪哲医药价值和创新药板块的中长期 关注和认可。 ...